A food supplement manufacturer should define who approves formula, material and label changes before the first commercial order moves into production.
A sample can look correct while the documents behind it remain unsettled. An ingredient supplier may change, a flavour may be adjusted, or artwork may be revised after a buyer has approved the taste. Each change can affect a different part of the product. The useful purchasing question is therefore who can propose a change, who must assess it, and which version the next batch will follow.
For an Australian brand owner, that discussion also needs a defined market and intended presentation. A catalogue category or a familiar dosage format does not settle whether a particular product is regulated as food or as a therapeutic good. Classification and the applicable requirements should be established for the actual formulation, claims and intended use before approving commercial artwork.
Start With A Product Definition That Has An Owner
Separate The Brief From The Approved Specification
The brief describes the desired outcome: format, flavour, target user, package size and sales market. The specification describes what will be made and how acceptance will be decided. A phrase such as “an orange electrolyte powder” leaves room for several formulations and package configurations. An approved specification needs an identifier, revision date and named approvers, together with the agreed attributes and their acceptance criteria.
The product catalogue can help identify available formats, but it is a starting point for discussion. The OEM and ODM service scope should be translated into a project-specific responsibility list. A buyer should know whether the manufacturer is developing a formula, making a supplied formula, sourcing packaging, preparing artwork, or coordinating these activities. Those responsibilities should not be inferred from a quotation heading.
Keep The Market Assessment Attached To The Version
Australian classification should be assessed using the current product composition, intended use and representations. A later formula revision or a new claim can change the questions that need review. The TGA food–medicine interface guidance provides a framework for examining that boundary; it does not make every product called a supplement a medicine, nor does it approve a supplier's entire catalogue.
A practical record identifies who obtains the market assessment, what information they used and which unresolved points block release. The manufacturer supplies accurate technical information within its scope. The brand owner and relevant advisers review market-facing obligations. Any division of tasks should be explicit, because forwarding an attractive label design does not demonstrate that its claims have been assessed.
Make Change Approval A Defined Decision
Describe What Changed Before Asking For A Signature
A change request should explain the current state, proposed state, reason and affected items. “Equivalent ingredient” is not a complete description. Reviewers may need the material identity, grade, origin, supplier, relevant characteristics and supporting documents. For a packaging change, the affected items could include the container, closure, liner, printed film, outer carton or storage instructions.
The food supplement manufacturer should also identify what remains unchanged and the basis for that statement. A flavour adjustment may leave the container unchanged while affecting ingredient declarations or sensory acceptance. A new sachet film may leave the recipe unchanged while requiring a packaging suitability review. The scope of the assessment should follow the change, rather than treating every revision as either harmless or a complete redevelopment.
Distinguish Approval To Trial From Approval To Supply
Permission to make a development sample should not be mistaken for permission to supply commercial stock. A useful approval path separates the proposed trial, the evidence to collect and the final decision. It also identifies who can place a batch on hold while questions are unresolved. This helps prevent a production schedule from becoming the only reason a change goes ahead.
Where the supplier's facility information mentions development or testing activities, the buyer can ask which activities apply to the proposed change. An assessment should name the relevant method, sample, result and reviewer. A generic laboratory photograph or certificate image cannot show that a particular revised formula has been examined.
Connect Formula Revision To Label Approval
Use One Reference For Ingredients And Artwork
Artwork review becomes fragile when ingredient text is copied from an old email or a similar product. The label approval record should point to the current formula and package specification. Reviewers need to distinguish the approved information from draft design choices. Product name, ingredient declaration, serving information, warnings and storage wording should each have a clear source and an appropriate reviewer.
Different formats need their own review. A jar shown in the protein powder range and a single-serving sachet have different space, presentation and use considerations. They should not share artwork text simply because both contain a powder. Likewise, a multipack outer carton and its individual units need a documented relationship rather than an assumption that the same text fits both.
Control The Files Sent To Production
The final artwork should have a version identifier that survives transfer to the printer or packaging supplier. File names alone are weak controls if different files can carry the same name. A signed proof, controlled document record or other agreed method should show the approved content and distinguish it from superseded versions. The purchase order should refer to that version, not merely to “the latest label”.
Label approval also needs a response to obsolete stock. The parties should agree whether old printed material is quarantined, destroyed, returned or used under a specifically authorised transition. The decision depends on the reason for the change. A marketing layout update is not the same as correcting inaccurate information, and neither should be handled through an informal warehouse instruction.
A change is controlled when the decision, evidence and affected stock can be connected. An approval email without a defined version leaves that connection incomplete.
Keep Material Traceability Separate From Batch Release
Follow The Incoming Material Into The Batch
Material traceability connects incoming lots to the batches that used them. It should cover the relevant ingredients and packaging components, with identifiers that remain usable when material is split, transferred or partially consumed. The buyer does not necessarily need every internal production record, but the agreed evidence should allow an affected lot to be located and its use investigated.
TGA guidance for listed and complementary medicines discusses assessing suppliers and materials within that particular regulatory setting. Its scope should be respected. It is not a universal rule for every food product, and a formal GMP agreement should not be assumed mandatory for every raw-material supplier. The practical purchasing task is to establish the applicable framework and request evidence suited to the material, product and relationship.
Identify The Person Who Releases The Finished Batch
A formula revision approval does not by itself release the batch made from that formula. Batch release considers whether the actual manufacturing and packaging records meet the agreed requirements and whether deviations remain open. The release responsibility, required records and escalation route should be agreed in advance. A shipping date is a scheduling commitment, not a substitute for that decision.
The manufacturing partnership scope can be used to discuss communication between commercial, technical and quality contacts. A named account manager may coordinate a response, while a different authorised person makes a technical decision. Recording both roles helps keep a commercially convenient answer from being mistaken for a documented quality conclusion.
Use A Responsibility Table At The Handover
The following table is a discussion aid, not a universal allocation of legal duties. Each project should replace the suggested roles with named parties and the requirements that actually apply. The record is most useful when a reviewer can locate the supporting file without reconstructing a long chain of messages.
| Decision | Evidence To Connect | Role To Name |
|---|---|---|
| Formula revision | Old and new versions, reason, assessment and trial outcome | Technical proposer and authorised approver |
| Material substitution | Material identity, supplier evidence and affected batches | Material assessor and purchasing contact |
| Label approval | Formula reference, approved text and final artwork proof | Market information owner and artwork approver |
| Batch release | Required manufacturing records and deviation disposition | Authorised release role |
| Stock transition | Old and new packaging quantities and handling decision | Warehouse owner and approving role |
| Complaint investigation | Product code, lot, version, retained evidence and response | Investigation lead and brand contact |
FAQ
Can A Supplier Change An Ingredient Without Changing The Product Name?
A product name can remain the same while the formulation or ingredient source changes. The agreement should identify which changes require notice and approval, what assessment is needed, and how the affected version is recorded. An unchanged name does not demonstrate that nothing relevant changed.
Does An Approved Sample Cover Every Later Production Batch?
No. The sample establishes a reference for agreed attributes, while later batches still need the required production and release controls. The sample should be identified and retained under agreed conditions. Its role should not be stretched to cover attributes that were never assessed.
Who Should Check Whether A Product Is Food Or A Therapeutic Good?
The project should name a competent party to assess the actual product and intended Australian presentation using the applicable requirements. The supplier must provide accurate technical information within its scope. A catalogue label, dosage form or marketing term alone cannot settle the classification.
Is A New Label Colour Always A Major Change?
Not necessarily. The assessment depends on what changed and its consequences. A colour adjustment may be a design matter, but it can also affect legibility or product differentiation. The important point is to record the assessment and the approved artwork rather than assume that every visual change is trivial.
What Should Be Sent Before A Supplier Review Meeting?
A concise package should include the intended market, product brief, current specification, proposed claims, package format and unresolved questions. An example change request is useful. It lets the parties discuss an actual decision path instead of exchanging general promises about quality.
Close The Responsibility Gaps Before The Next Order
A food supplement manufacturer is easier to evaluate when the buyer can trace one product version through formula, materials, artwork and batch release. The review should end with named decision owners and a list of unresolved evidence, rather than a general statement that all departments will cooperate.
For a project discussion, a buyer can send the current brief and the responsibility table through the supplier contact page, asking which records and approvals the proposed scope includes. A final order should refer to the agreed versions and transition arrangements so that a later change can be reviewed against a clear baseline.
